ERNA-101 Phase 1 Study Planned for Q4 2026: Complete Tumor Clearance in Preclinical Ovarian Cancer Models
Market Chameleon (Wed, 15-Jul 9:52 AM)
ERNA-101 Combination Therapy Achieves 67% Complete Tumor Clearance in Independent Ovarian Cancer Study
Market Chameleon (Wed, 15-Jul 8:10 AM)
